BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Meeting17-11-2022
17-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that India Ratings and Research (Ind-Ra) has assigned the rating for the following instruments- proposed commercial paper, Term loans-ECB and proposed term loans.16-11-2022
BIOCON LTD. - 532523 - Clarification Sought from Biocon Ltd
The Exchange has sought clarification from Biocon Ltd with reference to the media report appearing on https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-biologics-secures-regulatory-approvals-for-acquisition-of-viatris-biosimilar-business/articleshow/95548301.cms (Source: https://economictimes.indiatimes.com) dated November 16, 2022 titled "Biocon Biologics secures regulatory approvals for acquisition of Viatris'' biosimilar business'.The Company is requested to submit its clarification to the Exchange in terms of the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015.16-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated November 14, 2022 with regard to the Unaudited Financial Results for the quarter and half-year ended September 30, 2022, please find enclosed copies of newspaper advertisement published in Financial Express (English Language-All India Edition) and Vijayavani (Kannada-Bengaluru Edition) on November 16, 2022. The above information is also available on the website of the Company at www.biocon.com.16-11-2022
Results Earnings Call for Q2FY23 of Biocon Ltd.
Conference Call with Biocon Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: Kiran Mazumdar Shaw and Senior Team16-11-2022
Indian pharma will benefit from research-linked sops'
We are back to business now, and with our 100% operations focusing on all the opportunities that were lost during covid, says, Kiran Mazumdar-Shaw, executive chairperson, Biocon and Biocon Biologics16-11-2022
BIOCON LTD. - 532523 - Presentation And Video Recording Of Q2 FY23 Earnings Call
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find enclosed the presentation on Q2 FY23 Earnings Call conducted today i.e. on November 15, 2022. The same is also available on the website of the Company at www.biocon.com. Further, the Video Recording w.r.t. the Earnings Call is also available on the website of the Company at https://www.biocon.com/news-biocon/video-gallery-biocon/quarterly-statements-biocon/#1653297216088-5a4e9281-2d49.15-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to the captioned subject, please find enclosed the Investor Presentation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'). The above information will also be available on the website of the Company at www.biocon.com.15-11-2022
Q2FY23 Quarterly Result Announced for Biocon Ltd.
Biotechnology company Biocon announced Q2FY23 results: Biocon Q2FY23 revenue at Rs 2,384 crore, up 23% Core EBITDA at Rs 816 crore, up 34% Gross R&D; spend at Rs 252 crore, up 52% Biosimilars up 34%; research services up 26%; generics up 18% “We reported a strong consolidated revenue growth of 23% YoY for Q2FY23 at Rs 2,384 crore driven by 34% growth in Biosimilars, 26% in Research Services and 18% in the generics business. Our gross R&D; spending increased by 52% YoY this quarter to Rs 252 crore reflecting our advancing pipeline that will drive our future growth. Core EBITDA was up by 34% at Rs 816 crore, representing healthy core operating margins of 35% versus 33% in the same quarter last year. “We have delivered a resilient performance in H1FY23, with all segments delivering strong revenue growth. We expect to consolidate this performance in the second half of FY23. Enhanced capacities and new launches will drive growth for our API and Generic Formulations business, while continued business momentum should help Syngene achieve its guidance for the full year. “The consolidation of Viatris’ global biosimilars business and the strategic vaccines alliance with Serum Institute will add to the growth of the Biosimilars business in H2FY23. We have secured necessary financing and obtained relevant approvals for the Viatris transaction, which is expected to close shortly,” said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics. “I am pleased with the sequential as well as YoY growth of the Generics business in Q2, on the back of the stabilisation of our API business, with immunosuppressants being a significant contributor. Our statins portfolio continued to encounter pricing pressures. “Our Generic Formulations business delivered a healthy performance in the quarter, with both base business as well as new product launches gaining traction. The business also secured several key approvals for our vertically integrated products in the EU and the rest of the world (RoW) markets, providing further impetus to our geographical expansion plans in the quarters ahead," said Siddharth Mittal, CEO & Managing Director, Biocon. “Biocon Biologics maintained a healthy operating performance in Q2FY23 with revenues increasing 34% YoY to Rs 997 crore, driven by higher sales of our biosimilar insulins and antibodies in advanced and emerging markets. We have seen an uptick in new prescription share for Semglee and volume market share for Fulphila in the US. Core EBITDA at Rs 449 crore was up 48% YoY, representing strong margins of 46%. R&D; investments at Rs 184 crore, an increase of 142% YoY, reflects the good progress of our pipeline laying the foundation for future growth of our business. “In preparation for a direct commercial presence in the advanced markets, we have made key leadership appointments this quarter. We believe the conclusion of the strategic transactions with Viatris and Serum Institute, expected to be closed in Q3FY22, will position Biocon Biologics as a fully integrated, leading global biosimilars player,” said Dr Arun Chandavarkar, Managing Director, Biocon Biologics. “Our performance in the first half of the year was good. We started the year with strong momentum and delivered a robust first quarter. Performance in the second quarter was ahead of market expectations. All our divisions performed well and revenue from operations grew by 26%. We continue to see good demand for our services, which has helped us deliver strong revenue growth and puts us on a solid track for the rest of the year,” said Jonathan Hunt, CEO & Managing Director, Syngene. Result PDF15-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled 'Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% ; Gross R&D Spend at Rs 252 Crore, Up 52%; Biosimilars Up 34%; Research Services Up 26%; Generics Up 18%' pertaining to the un-audited consolidated financial results of Biocon Limited for the quarter and half year ended September 30, 2022. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the above information on record and acknowledge.14-11-2022